Fujifilm Diosynth To Invest $1.6 Bn to Expand Cell-Culture Mfg
Fujifilm Diosynth Biotechnologies has announced an investment of $1.6 billion to enhance and expand cell-culture manufacturing at its sites in Hillerød, Denmark, and College Station, Texas.
The company is expanding to support large-scale cGMP fed-batch production by adding 8 x 20,000-L bioreactors and two downstream processing streams in its Hillerød, Denmark, facility to provide a total of 20 x 20,000-L bioreactors for drug-substance production as well as drug-product and finished goods services.
The company will also expand cell-culture manufacturing at its site in College Station, Texas, by implementing the company’s proprietary manufacturing platforms: MaruX for upstream and downstream continuous biomanufacturing and SymphonX, an automated and downstream purification system.
